scorecardresearch
Thursday, July 24, 2025
TopicRemdesivir

Topic: Remdesivir

Approved by US, rejected by WHO — science of remdesivir & why it has turned controversial

The controversy around remdesivir use stems from divergent claims about its efficacy among patients, and appears to centre on the stage at which it should be administered to patients.

Busting Covid myths on plasma therapy and remdesivir, and what India’s falling numbers mean

In episode 602 of #CutTheClutter, Shekhar Gupta analyses India's declining Covid numbers, and explains the science behind remdesivir and plasma therapy.

ICMR recommends dropping Interferon, adding cancer drug Acalabrutinib to WHO Solidarity trial

ICMR has submitted a proposal to the Modi govt recommending the cancer drug developed by AstraZeneca, which apparently improved clinical outcomes of patients with severe Covid-19.

Remdesivir is first Covid drug to get US FDA approval

The approval of remdesivir, sold under the brand name Veklury, will allow Gilead to market the drug and talk about its benefits to doctors, nurses, and patients.

ICMR recalls statement that said WHO’s Solidarity Trial plans to continue testing remdesivir

Remdesivir, along with HCQ, lopinavir and interferon, have shown no benefits on Covid patients in WHO's multi-national Solidarity Trial.

Gilead questions trial design after WHO says its remdesivir is ineffective against Covid

In a statement issued Thursday, Gilead Sciences noted that Solidarity trial's interim findings on remdesivir have 'not undergone the rigorous review'.

Remdesivir, HCQ, lopinavir & interferon have no effect on Covid patients — Solidarity trial

In a paper on the interim findings on the four drugs, WHO's Solidarity trial researchers in 30 countries return a clear negative.

AYUSH scientists slam IMA for calling their systems ‘unscientific’, question HCQ & remdesivir

Doctors’ body had questioned health minister for promoting AYUSH, but AYUSH scientists ask why HCQ was used despite no evidence that it’s effective.

Ashwagandha, kadha, guduchi — Modi govt issues official ayurveda protocol for mild Covid

A selection of the best news reports, analysis and opinions published by ThePrint this week.

RSS affiliate tells Modi govt to cancel remdesivir patent & act against ‘greedy’ pharma MNCs

In a letter to Modi, Swadeshi Jagran Manch requested the PM to cancel the patent on remedsivir, which it said was granted 'against the provisions of Indian Patents Act'.

On Camera

Defence, tech, education—Modi’s visit will boost India-UK ties

Given the immediate challenges on India’s borders, cooperation in the defence sector with partners such as the UK has achieved greater importance.

India-US set to ink mini trade deal soon, reach understanding on agricultural & dairy products

Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.

Indian firm sets up titanium, superalloy plants to meet global need. Safran, Dassault, BAE line up

PTC Industries is investing Rs 1,000 cr in 4 manufacturing plants in UP, has already started supplying titanium parts to BAE Systems for its M-777 howitzers that India also uses.

Strategic partner one day, tactical nightmare the next: India’s learning Trumplomacy the hard way

Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.